CARMAT unveils interim data on autoregulation from PIVOTAL trial
Category: #health  By Paroma Bhattacharya  Date: 2019-07-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

CARMAT unveils interim data on autoregulation from PIVOTAL trial

France-based CARMAT, the developer of the most advanced total artificial heart in the world aimed at offering therapeutic alternatives for end-stage biventricular heart failure patients, has recently released additional interim data from the PIVOTAL study in San Francisco, California, at the American Society for Artificial Internal Organs (ASAIO) Annual Conference 2019.

Citing reliable sources, CARMAT unveiled results concerning autoregulation, a unique characteristic of bioprosthesis which allows the blood flow to automatically adapt to patient requirements owing to the use of integrated sensors and intelligent control algorithms.

Apparently, all the patients in the first cohort had benefited from this autoregulation successfully, as soon as they were implanted, which led to immediate and lasting hemodynamic recovery. This provided the ideal conditions for restoration of their vital functions.

Sources mentioned that the principles and responsiveness of autoregulation need only a negligible number of adjustments, allowing doctors to concentrate on the patient’s clinical monitoring. Through a standard rehabilitation process, after being in intensive care of nearly 8 days, patients were seemingly able to leave for home within 2 months of the implant.

Reportedly, due to CARMAT prosthesis, patients could spend about 70% of their time at home enjoying a quality of life and performing usual day-to-day activities.

According to the sources, another heart transplant was performed successfully within the PIVOTAL study’s framework. This increased the number of people that have received donor hearts, post taking advantage of the support of CARMAT prosthesis for several months, to 5 patients as of now.

Within the framework of PIVOTAL study, the prosthesis has achieved a record 16 months of individual support till date, along with 6 years and 3 months of cumulative support in the total 11 patients who were implanted.

CARMAT CEO Stéphane Piat said that the positive additional results from PIVOTAL trial reinforces the confidence of the company in the capabilities of the prosthesis in providing safe, efficient solutions to patients suffering from biventricular heart failure.

Source Credits: https://www.carmatsa.com/carmat-content/uploads/2019/07/pr_carmat_asaio_en.pdf



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.